0000000000448827

AUTHOR

Zaida García-casado

showing 3 related works from this author

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuva…

2009

Abstract Background Aromatase (CYP19A1) regulates estrogen biosynthesis. Polymorphisms in CYP19A1 have been related to the pathogenesis of breast cancer (BC). Inhibition of aromatase with letrozole constitutes the best option for treating estrogen-dependent BC in postmenopausal women. We evaluate a series of polymorphisms of CYP19A1 and their effect on response to neoadjuvant letrozole in early BC. Methods We analyzed 95 consecutive postmenopausal women with stage II-III ER/PgR [+] BC treated with neoadjuvant letrozole. Response to treatment was measured by radiology at 4th month by World Health Organization (WHO) criteria. Three polymorphisms of CYP19A1, one in exon 7 (rs700519) and two in…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAnastrozoleAntineoplastic AgentsBreast Neoplasmslcsh:RC254-282AromataseBreast cancerSurgical oncologyInternal medicineNitrilesGeneticsmedicineHumansAromatase3' Untranslated RegionsNeoadjuvant therapyAgedAged 80 and overPolymorphism GeneticAromatase inhibitorbiologybusiness.industryLetrozoleMiddle AgedTriazoleslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryNeoadjuvant TherapyPostmenopauseTreatment OutcomeEndocrinologyOncologyLetrozoleDisease Progressionbiology.proteinFemalebusinessTamoxifenResearch Articlemedicine.drugBMC Cancer
researchProduct

Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatect…

2014

Purpose: miRNAs are noncoding RNAs that negatively regulate target mRNA gene expression. Aberrant miRNA expression is associated with prostate cancer pathogenesis. We identified miRNAs as potential biomarkers for prostate cancer diagnosis and prognosis. Materials and Methods: Total RNA was obtained from 10 normal prostate and 50 prostate cancer samples, and analyzed using the GeneChip (R) miRNA 2.0 Array. At a median followup of 92 months (range 2 to 189) an independent cohort of 273 paraffin embedded prostate cancer samples was used for validation by quantitative reverse transcriptase-polymerase chain reaction. Another 92 urine samples from patients undergoing prostate biopsy were evaluate…

PCA3OncologyMalemedicine.medical_specialtyPathologyProstate biopsydiagnosisUrologymedicine.medical_treatmentprostatic neoplasmsProstate cancerProstateInternal medicinemicroRNAmedicineBiomarkers TumorHumansAgedRetrospective StudiesProstatectomymedicine.diagnostic_testbusiness.industryProstatectomyProstatic Neoplasmsmedicine.diseasePrognosismicroRNAsGene Expression Regulation NeoplasticProstate-specific antigenMicroRNAsmedicine.anatomical_structureReal-time polymerase chain reactionEarly Diagnosisprognosisbusinessbiological markersThe Journal of urology
researchProduct

The association between dermoscopic features and BRAF mutational status in cutaneous melanoma: Significance of the blue-white veil.

2018

Background: The genetic basis of melanoma affects its clinicopathologic characteristics and increasingly influences its management. B-Raf proto-oncogene, serine/threonine kinase gene (BRAF)-mutated melanoma may present with specific dermoscopic features. Objectives: To identify the dermoscopic features associated with BRAF mutation in cutaneous melanoma and to evaluate a model capable of predicting BRAF mutations on the basis of dermoscopic and clinicopathologic features that are easily accessible in normal clinical practice. Methods: A prospective, cross-sectional, observational, and descriptive study was performed. A total of 93 cutaneous melanomas with dermoscopic images from 93 patients…

OncologyMaleSkin NeoplasmsDNA Mutational Analysisblue-white veilProto-Oncogene Mas030207 dermatology & venereal diseases0302 clinical medicineBRAF V600 MutationOdds RatioMutational statusgeneticsProspective StudiesMelanomaSanger sequencingMelanomaMiddle AgedPrognosisClinical PracticedermatologyGene Expression Regulation Neoplastic030220 oncology & carcinogenesisoncologysymbolsFemaleAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyDermoscopyDermatologyRisk AssessmentBRAF03 medical and health sciencessymbols.namesakePredictive Value of TestsInternal medicinemedicinemelanomaConfidence IntervalsHumansneoplasmsAgedbusiness.industryOdds ratiostreaksmedicine.diseaseConfidence intervalulcerationCross-Sectional StudiesCutaneous melanomapathologydermoscopybusinessexophytic papillary structuresJournal of the American Academy of Dermatology
researchProduct